Terminated PHASE3 INTERVENTIONAL 4-arm NCT00599287

Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients

Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients: a Randomized, Mono-blind Pilot Trial

Sponsor: UMC Utrecht

Conditions Delirium

Interventions Haloperidol Methylphenidate Rivastigmine

Updated 10 times since 2017 Last updated: Mar 19, 2018 Started: Feb 29, 2008 Primary completion: May 31, 2008 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Inclusion rate too low due to a lack of eligible patients and difficulties obtaining informed consent.

A PHASE3 clinical study on Delirium, this trial is terminated or withdrawn. The trial is conducted by UMC Utrecht and has accumulated 10 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Jun 2018 — Nov 2020 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Apr 2018 — May 2018 [monthly]

Terminated PHASE3
Aug 2017 — Apr 2018 [monthly]

Terminated PHASE3
Jan 2017 — Aug 2017 [monthly]

Terminated PHASE3

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UMC Utrecht

Data source: UMC Utrecht

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Utrecht, Netherlands